Corbus Pharmaceuticals Holdings, Inc.
CRBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $16 | $0 |
| Gross Profit | $0 | -$0 | -$16 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $21 | $15 | $16 | $9 |
| G&A Expenses | $0 | $4 | $4 | $0 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$16 | $0 |
| Operating Expenses | $24 | $19 | $4 | $12 |
| Operating Income | -$24 | -$19 | -$20 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $3 | $3 |
| Pre-Tax Income | -$23 | -$18 | -$17 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$23 | -$18 | -$17 | -$10 |
| % Margin | – | – | – | – |
| EPS | -1.9 | -1.44 | -1.39 | -0.78 |
| % Growth | -31.9% | -3.6% | -78.2% | – |
| EPS Diluted | -1.9 | -1.44 | -1.39 | -0.78 |
| Weighted Avg Shares Out | 12 | 12 | 12 | 12 |
| Weighted Avg Shares Out Dil | 12 | 12 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $2 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$23 | -$18 | -$19 | -$9 |
| % Margin | – | – | – | – |